Cingulate Inc (CING)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.10-2.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Cingulate plans to resubmit the CTx-1301 NDA promptly after FDA feedback. The company raised $12 million in private placements to support operations. Operating losses are managed near -$7.9 million in Q1 2026. Analysts expect EPS loss to improve from -$2.63 to -$2.3 in 2026.
FDA's Complete Response Letter delays approval and raises regulatory risk. Operating losses remain high with no clear path to profitability. The company is loss-making with negative free cash flow yield of -0.89. Analyst EPS estimates remain negative through 2027.
The market is selling off sharply after the FDA CRL, reflecting heightened regulatory risk. There is no clear consensus revenue or EPS growth priced in, and the stock trades with high risk given ongoing losses and uncertainty.
Breaks if: Capital runs out before end of FY26 without further funding
Breaks if: NDA resubmission delayed beyond next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with high volatility. The current thesis state is cautious, as the company is navigating challenges while trying to advance its product pipeline and commercial readiness.
The market appears to have priced in significant uncertainty, given the company's loss-making status and recent mixed earnings performance. Investors may expect continued volatility, especially in light of broader economic concerns affecting the healthcare sector.
Fundamentals are likely to remain unstable in the near term due to high risk and mixed management execution. While the company has made progress in strengthening its financial position, the potential for earnings misses remains a concern.
The long-term thesis hinges on the company's ability to successfully resubmit its NDA for CTx-1301 and advance its commercial readiness. Additionally, the performance of sector bellwethers like VRTX, REGN, and ARGX will be crucial in determining the overall momentum in the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company plans to resubmit its CTx-1301 NDA to the FDA. This advancement in their drug development supports a more favorable outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating loss worsens beyond -$7.9 million per quarter
Control operating expenses and losses while advancing development and commercial readiness.
Stated as a priority in 2 of last 2 quarters. Net loss increased from $5.0 million in 2025-Q2 to $5.9 million in 2026-Q2, reflecting higher SG&A expenses for commercial readiness despite reduced R&D costs. Management continues to manage operating losses amid advancing development and commercialization efforts, showing limited progress in reducing net losses.
“Net loss was $5.9 million for the three months ended June 30, 2026, compared to $5.0 million for the same period in 2025.”
“Net loss was $9.3 million for the three months ended March 31, 2026, compared to $3.9 million for the same period in 2025.”
In the next 1 to 3 years, CING's prospects will depend heavily on regulatory outcomes and sector performance. Not investment advice.